Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Equity Average (2021 - 2025)

Lyra Therapeutics has reported Equity Average over the past 5 years, most recently at -$7.5 million for Q4 2025.

  • Quarterly results put Equity Average at -$7.5 million for Q4 2025, down 146.7% from a year ago — trailing twelve months through Dec 2025 was -$7.5 million (down 146.7% YoY), and the annual figure for FY2025 was $438500.0, down 99.13%.
  • Equity Average for Q4 2025 was -$7.5 million at Lyra Therapeutics, down from -$1.4 million in the prior quarter.
  • Over the last five years, Equity Average for LYRA hit a ceiling of $99.7 million in Q3 2022 and a floor of -$7.5 million in Q4 2025.
  • Median Equity Average over the past 5 years was $54.2 million (2024), compared with a mean of $50.1 million.
  • Biggest five-year swings in Equity Average: surged 155.06% in 2023 and later plummeted 146.7% in 2025.
  • Lyra Therapeutics' Equity Average stood at $40.8 million in 2021, then skyrocketed by 113.46% to $87.0 million in 2022, then decreased by 0.18% to $86.8 million in 2023, then tumbled by 81.45% to $16.1 million in 2024, then plummeted by 146.7% to -$7.5 million in 2025.
  • The last three reported values for Equity Average were -$7.5 million (Q4 2025), -$1.4 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.